CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Wuhan YZY Biopharma Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Wuhan YZY Biopharma Co Ltd
No. 666 Gaoxin Road
East Lake High Tech Development Zone
Phone: +86 2782668988p:+86 2782668988 WUHAN, HUB  430075  China Ticker: 24962496
Business Summary
Wuhan YZY Biopharma Co Ltd is a China-based company mainly engaged in the discovery, development, and commercialization of new innovative drugs in the field of anti-tumor bispecific antibodies. The Company is committed to developing bispecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer, and age-related eye diseases to address the medical needs in oncology and geriatric eye diseases. The Company is still in the research and development stage. The Company's core product M701 is a recombinant BsAb that targets human cancer cell surface antigen EpCAM and human T cell surface antigen CD3. The Company's product pipeline also includes Y101D, Y332, Y225, and others.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder, General Manager PengfeiZhou
Senior Vice President - Quality JizuYi 12/1/2019 12/1/2019
Vice President - Production Center BinYang
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 114 (As of 6/30/2024)
Outstanding Shares: 193,849,200 (As of 6/30/2024)
Stock Exchange: HKG
Fax Number: +86 2768788819


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, January 31, 2025